(D20) Changing the Map of T1D Care: Navigation of a Pediatric Teplizumab Program

Sunday, August 9, 2026

1:55 PM - 2:40 PM ET

CE: .75 CE

Pharmacology Hours: .25 CE

Until recent innovations in diabetes prevention and treatment became available, a type 1 diagnosis was often swift and unexpected, leading to frequent admissions to the hospital with DKA. This session will explore implementation of our Early T1D Program, designed to identify early indicators of diabetes progression leading to increased access to successful Teplizumab infusions (an FDA-approved therapy shown to delay the onset of stage 3, type 1 diabetes). We will discuss how this proactive approach prevents severe illness, reduced trauma, and lessens the educational demands placed on children and their families early in type 1 diabetes diagnosis.

Learning Objectives:

At the completion of this activity, participants should be able to:

Describe clinical and educational components required to implement an early screening and teplizumab infusion program in a pediatric diabetes institute.
Identify strategies that support safe administration, efficient scheduling, and multidisciplinary coordination for patients eligible for teplizumab therapy.
Evaluate how programs can improve patient access to Teplizumab therapy and support early intervention for youth with early T1D.

Disclosure(s):

Mikyla Peres, MS, RDN, LD/CN, CDCES, MLDE: No financial relationships to disclose

Jaime Walker, DNP, MSN, RN, CDCES: No financial relationships to disclose

Primary Presenter(s)

Mikyla Peres, MS, RDN, LD/CN, CDCES, MLDE

Director, Diabetes Education & Programming
Wendy Novak Diabetes Institute - Norton Healthcare

Disclosure(s): No financial relationships to disclose

Co-Presenter(s)

JW

Jaime Walker, DNP, MSN, RN, CDCES

Clinical Nurse Manager
Norton Children's - Wendy Novak Diabetes Institute

Disclosure(s): No financial relationships to disclose